Matthew Rettig, M.D.
Matthew Rettig, M.D. is an Associate Professor in the Department of Medicine, Division of Hematology-Oncology, and the Department of Urology, and is the Medical Director of the Prostate Cancer Program of the Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. After receiving his medical degree from Duke University , Dr. Rettig completed internal medicine residency at the University of Washington before going on to a hematology-oncology fellowship at UCLA.
As a medical oncologist, he focuses on the management of genitourinary malignancies with a focused clinical emphasis on advanced prostate cancer. Dr. Rettig has both a clinical and bench research program. As the director of the clinical trials program in prostate cancer at UCLA, he conducts multiple prostate cancer clinical trials that span the spectrum of the states of the disease: from neoadjuvant therapies to post-chemotherapy, castration-resistant disease. Dr. Rettig’s bench research program, which is funded by the NIH, Department of Defense and the Department of Veterans Affairs, is focused on identifying biochemical targets for therapeutic translation in castration-resistant prostate cancer and clear cell renal cell carcinoma.